Press Releases

US test maker Cepheid and parent corporation Danaher have ignored global calls for price reductions and have broken their promise from one year ago to be transparent about what it costs to make their medical tests. More

Time for $5 Campaign demands Cepheid reduce price of HIV, TB and hepatitis C tests to $5 each. More

Several Ministries of Health have written to Danaher requesting that the price of the tests for XDR-TB, HIV and hepatitis — currently priced at $14.90 per test cartridge — also be lowered to no more than $7.97. More

Following the appeal filed by AIDES, Médecins du Monde and Médecins sans Frontières, the European Patent Office has decided to uphold the patent of sofosbuvir, hindering the launch of an affordable generic version of the drug in Europe. More

Ravidasvir is the first HCV cure to be developed through South-South collaboration and with funding and clinical support from non-profit organizations. It is now recommended for use in combination with sofosbuvir as an alternative pangenotypic DAA. More

Four years after MPP and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers, generic G/P is not available anywhere. More

Advocates call out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urge the company to reinstate plans to launch Omni. More

Hepatitis C PACT will work in Latin America, Asia, Africa, and Eastern Europe — collaborating with “champion countries” that are already revolutionizing hepatitis care. More

An open letter sent to Unitaid demands continuous investment towards HBV and HCV elimination, and to address the needs of 354 million people living with viral hepatitis worldwide. More

An open letter sent to the UK and EU heads of state, and European Commission leadership urging for immediate provision of COVID-19 vaccines to all migrants residing in the UK and EU. More